<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25212951</article-id><article-id pub-id-type="publisher-id">5019</article-id><article-id pub-id-type="doi">10.1186/1471-2407-14-663</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Histopathology-based prognostic score is
independent prognostic factor of gastric carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhu</surname><given-names>Zhi</given-names></name><address><email>zhuzhi@yeah.net</email></address><xref ref-type="aff" rid="Aff18"/><xref ref-type="aff" rid="Aff19"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Sun</surname><given-names>Xuren</given-names></name><address><email>sxr679@126.com</email></address><xref ref-type="aff" rid="Aff20"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jinou</given-names></name><address><email>jinouwang@126.com</email></address><xref ref-type="aff" rid="Aff21"/></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Zhe</given-names></name><address><email>asray@sina.com</email></address><xref ref-type="aff" rid="Aff18"/><xref ref-type="aff" rid="Aff19"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Zhenning</given-names></name><address><email>josieon826@sina.cn</email></address><xref ref-type="aff" rid="Aff18"/><xref ref-type="aff" rid="Aff19"/></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Xinyu</given-names></name><address><email>xyzheng126@126.com</email></address><xref ref-type="aff" rid="Aff18"/><xref ref-type="aff" rid="Aff19"/><xref ref-type="aff" rid="Aff21"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Xu</surname><given-names>Huimian</given-names></name><address><email>xuhuimian@126.com</email></address><xref ref-type="aff" rid="Aff18"/><xref ref-type="aff" rid="Aff19"/></contrib><aff id="Aff18"><label/>Department of Surgical Oncology, First Affilated Hospital, China Medical University, North Nanjing Street 155, Shenyang, 110001 PR, China </aff><aff id="Aff19"><label/>Department of General Surgery, First Affiliated Hospital, China Medical University, Shenyang, China </aff><aff id="Aff20"><label/>Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang, China </aff><aff id="Aff21"><label/>Department of Pathology, Shengjing Hospital of China Medical University, Shenyang, China </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>14</volume><elocation-id>663</elocation-id><history><date date-type="received"><day>10</day><month>5</month><year>2014</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Zhu et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is
an Open Access article distributed under the terms of the Creative Commons
Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited. The Creative Commons
Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless
otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>The aim of our study was to evaluate the histological characteristics and
prognosis of gastric cancer.</p></sec><sec><title>Methods</title><p>Clinicopathlogical variables of 932 patients with gastric carcinoma admitted
to the Department of Surgical Oncology at the First Hospital of China Medical
University were analyzed retrospectively. Different histological characteristics
of gastric cancer were summarized and assigned score according to the malignancy
defined by WHO classification, the scores were stratified into 4 stage, the
prognosis of different stages were analyzed by Kaplan-Meier analysis and cox
regression.</p></sec><sec><title>Results</title><p>Among the 932 patients, 246 (26.39%) had mixed histology type of gastric
cancer. Compared to the pure histological type, mixed histological type of gastric
cancer was significant associated with tumor size, lymph node metastasis and depth
of invasion (all P&#x02009;&#x0003c;&#x02009;0.05). The 5-year survival rates of advanced and early
gastric cancer patients with mixed type were 40.8% and 83.5% respectively, which
were lower than those with pure type (50.0% and 95.8%, P&#x02009;&#x0003c;&#x02009;0.01). Statistically
significant difference with stratification of early and advanced stage could be
observed between patients with the histological grading score. The data showed
that the histological score could be the independent factor of prognosis.</p></sec><sec><title>Conclusions</title><p>The histological score is an independent factor of gastric cancer, it exerts
an excellent ability to classify survival of patients with gastric carcinoma. It
also provides a new strategy and parameter for evaluating the biological behavior
and prognosis of gastric cancer.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Gastric cancer</kwd><kwd>Histological type</kwd><kwd>Tumor differentiation</kwd><kwd>Prognosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>It might be easily thought out that tumor-related factors such as tumor size,
lymphatic invasion, and venous invasion could be an indicator for progressive
potential of malignant tumors [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. However, except
for stage of the tumor, there have not been any criteria using histopathological
tumor-related factors to determine the outcome of the patients with gastric
carcinoma.</p><p>Histopathological type is an important prognosis factor, it is also to determine
the extent of surgical resection and formulated the basis for reasonable surgical
plan [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. It plays an important role in prognostic score for a variety of
tumors, such as Gleason score for prostate cancer [<xref ref-type="bibr" rid="CR6">6</xref>], Child-pugh classification for hepatocellular carcinoma
[<xref ref-type="bibr" rid="CR7">7</xref>], SBR, WHO score for breast cancer
[<xref ref-type="bibr" rid="CR8">8</xref>], but the prognostic effect of
histopathology has never been reported in gastric cancer. Moreover, there is not any
effective way to identify the prognosis of early gastric cancer.</p><p>The coexistence of different histological types of gastric cancer determines the
the complex characteristics of clinical behavior and prognosis, the mixed
histological type accounted for over 25% of all gastric cancer [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Since major diagnostic principles are used, the highly
heterogeneous histological features of gastric cancer were ignored, tumor biological
behavior and prognostic value of minor histological type were coved up [<xref ref-type="bibr" rid="CR11">11</xref>]. We currently evaluated the prognostic
significance of WHO histological classification of gastric cancer with a new
histological scoring method, which makes the histopathological variable to be an
independent prognostic factor.</p><p>In this study, we attempted to evaluate the histological characteristics and
establish simple criteria using the results of histopathological tumor-related
factors to predict prognosis of patients with gastric carcinoma.</p><sec id="Sec2"><title>Methods</title><p>All patients with gastric cancer who underwent surgery at the Department of
Surgical Oncology, First Hospital of China Medical University, during January 1980
to December 2006 were entered into a prospectively maintained database. Ethical
approval for this research was obtained from the Research Ethics Committee of
China Medical University, China. In total, 1077 patients underwent D2
lymphadenectomy and achieved radical (R0) resection for histologically proven
gastric carcinoma. Follow-up was complete for the entire study population to June
2005. Among them, 24 died in the postoperative period and 43 were lost to
follow-up. Thus, 145 patients were excluded. Of the remaining 932 patients, Median
and mean follow-up period were 31 and 54&#x000a0;months (range: 3&#x02013;313 months),
respectively. Patients were treated exclusively by total or subtotal gastrectomy
with lymphadenectomy, according to tumor location, adjuvant therapy or
postoperative chemotherapy was not administered to any patient. Cancer-specific
survival was calculated from the date of primary surgical resection to the date of
gastric cancer associated death or to the date of recorded cancer progression.
Tumor invasion (T), lymph node involvement (N) and TNM stage were classified
according to the 7<sup>th</sup> UICC/AJCC (2012) staging
systems.</p></sec><sec id="Sec3"><title>Histological grading</title><p>According to highly heterogeneous histological features and WHO classification
of gastric cancer, we propose the novel histological grading system. Aiming to
develop and validate the scoring system, the following statistical computing
methodologies were applied in the order indicated:<list list-type="order"><list-item><p>According to the previous studies of histological differentiation and
malignant degree of gastric carcinoma, non-mucinous adenocarcinoma
(papillary adenocarcinoma and high, medium and low differentiated tubular
adenocarcinoma) were assigned as 1&#x02013;3 points, respectively. Mucinous
adenocarcinoma was assigned as 3 points, signet ring cell carcinoma was
assigned as 4 points, undifferentiated carcinoma was assigned as 4 points,
a special type of stomach cancer as 4 points (these score still needs
further refinement) (Table&#x000a0; <xref rid="Tab1" ref-type="table">1</xref>).(2)
The total score of gastric carcinoma was summed by the original score of
the primary histological type and secondary type of gastric carcinoma.
Then the total score was divided by the number of histological types to
calculate the final score (The mean of the total score). If it was
composed of three or more histological type of gastric tissues, The scores
will aggregate all score of histological type, then divideded by the
number of histological types to get the final score, as presented in
Figure&#x000a0; <xref rid="Fig1" ref-type="fig">1</xref>. If the carcinoma was
composed of a pure histological type (All tumors were constituted by the
primary type), the score remains the final score.</p></list-item></list><table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Histological grading points of different subtypes of
gastric carcinoma</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Gastric carcinoma</th><th>Score</th></tr></thead><tbody><tr><td>Papillary carcinoma</td><td align="right">1</td></tr><tr><td>Tubular carcinoma</td><td align="right"/></tr><tr><td align="left">&#x02003;&#x02003;Well-differentiated</td><td align="right">1</td></tr><tr><td align="left">&#x02003;&#x02003;Medium-differentiated</td><td align="right">2</td></tr><tr><td align="left">&#x02003;&#x02003;Poorly-differentiated</td><td align="right">3</td></tr><tr><td>Mucinous gastric carcinoma</td><td align="right">3</td></tr><tr><td>signet-ring cell</td><td align="right">4</td></tr><tr><td>Undifferentiated gastric carcinoma</td><td align="right">5</td></tr><tr><td>Special type gastric carcinoma</td><td align="right">4</td></tr><tr><td align="left">&#x02003;&#x02003;Adeno-squamous carcinoma</td><td align="right"/></tr><tr><td align="left">&#x02003;&#x02003;Squamous cell carcinoma</td><td align="right"/></tr><tr><td align="left">&#x02003;&#x02003;Sarcomatoid type gastric cancer</td><td align="right"/></tr><tr><td align="left">&#x02003;&#x02003;Liver adenocarcinoma</td><td align="right"/></tr><tr><td align="left">&#x02003;&#x02003;Micro papillary carcinoma</td><td align="right"/></tr><tr><td align="left">&#x02003;&#x02003;Neuroendocrine carcinoma</td><td align="right"/></tr><tr><td align="left">&#x02003;&#x02003;Eosinophilic cell carcinoma</td><td align="right"/></tr></tbody></table></table-wrap><fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Mixed histological type of gastric cancer in WHO
classification. (A)</bold> high differentiated tubular
adenocarcinoma mixed with mucinous adenocarcinoma, final score:
(1&#x02009;+&#x02009;3)/2&#x02009;=&#x02009;2, <bold>(B)</bold> medium differentiated
tubular adenocarcinoma mixed with mucinous adenocarcinoma, final score:
(2&#x02009;+&#x02009;3)/2&#x02009;=&#x02009;2.5 <bold>(C)</bold> high differentiated
tubular adenocarcinoma mixed with signet ring cell carcinoma and mucinous
adenocarcinoma, final score: (1&#x02009;+&#x02009;3&#x02009;+&#x02009;4)/3&#x02009;=&#x02009;2.7, <bold>(D)</bold> high differentiated mixed with undifferentiated gastric
cancer, final score: (1&#x02009;+&#x02009;5)/2&#x02009;=&#x02009;3.</p></caption><graphic xlink:href="12885_2014_5019_Fig1_HTML" id="d30e490"/></fig></p><p><list list-type="simple"><list-item><label>(3)</label><p>Histological grading stage (H Stage) was divided into four groups
according to their scores, as follows: H1 (&#x02264;2 points), H2 (2&#x02013;3 points), H3
(3&#x02013;4 points) and H4 (4&#x02013;5 points).</p></list-item></list></p></sec><sec id="Sec4"><title>Statistical analysis</title><p>Each variable was used as an independent variable in a Cox proportional
hazards analysis run using the Kaplan-Meier method. This was done to screen the
variables for later inclusion in a multivariable model. To be included in the
multivariable analysis, a variable had to be significant at &#x003b1; of 0.1 for the Wald
test. This was a test of the null hypothesis that the coefficient for all levels
of the variable of interest was equal to zero.</p><p>All significant variables of the univariate analysis were included in the
first run of a multivariable Cox proportionate hazard regression. In subsequent
Cox regressions, significantly different variables in their hazard ratios were
remained sequentially based on the z-statistic for the individual levels of each
categorical variable. To remain in the final model, a variable had to be
significant at &#x003b1; of 0.05 at all levels.</p></sec></sec><sec id="Sec5" sec-type="results"><title>Results</title><p>As stated above, the study included 932 patients undergoing gastrectomy for
gastric carcinoma from 1980 to 2005. All patients followed until death or for a
maximum 313&#x000a0;months. The overall 5-year survival rate was 41.1%. Adjuvant and
chemotherapy treatment was rarely applied in this series. The frequencies of patient
characteristics and epidemiological results are summarized in Table&#x000a0; <xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Univariate analysis of the prognostic factors for
patients with gastric cancer in overall and early stage</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th colspan="4">Overall</th><th colspan="4">Early stage</th></tr><tr><th/><th>Cases</th><th>n(%)</th><th>5-year OS(%)</th><th>P value</th><th>Cases</th><th>n(%)</th><th>5-year OS(%)</th><th>P value</th></tr></thead><tbody><tr><td>Gender</td><td align="center">932</td><td align="center"/><td align="center"/><td align="center">0.311</td><td align="center">90</td><td align="center"/><td align="center">82.2</td><td align="center">0.07</td></tr><tr><td align="left">&#x02003;&#x02003;Male</td><td align="center">669</td><td align="center">71.8</td><td align="center">37.8</td><td align="center"/><td align="center">65</td><td align="center">72.2</td><td align="center">86.2</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Female</td><td align="center">263</td><td align="center">28.2</td><td align="center">43.1</td><td align="center"/><td align="center">25</td><td align="center">27.8</td><td align="center">72.0</td><td align="center"/></tr><tr><td>Age(years)</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.062</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.32</td></tr><tr><td align="left">&#x02003;&#x02003;&#x02264;65</td><td align="center">533</td><td align="center">57.2</td><td align="center">34.3</td><td align="center"/><td align="center">66</td><td align="center">73.3</td><td align="center">83.3</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;&#x0003e;65</td><td align="center">399</td><td align="center">42.8</td><td align="center">43.0</td><td align="center"/><td align="center">24</td><td align="center">26.7</td><td align="center">79.2</td><td align="center"/></tr><tr><td>Size</td><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x0003c;0.001</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.714</td></tr><tr><td align="left">&#x02003;&#x02003;&#x02264;4&#x000a0;cm</td><td align="center">224</td><td align="center">24.0</td><td align="center">59.2</td><td align="center"/><td align="center">57</td><td align="center">63.3</td><td align="center">82.5</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;&#x0003e;4&#x000a0;cm</td><td align="center">708</td><td align="center">76.0</td><td align="center">33.0</td><td align="center"/><td align="center">33</td><td align="center">36.7</td><td align="center">81.8</td><td align="center"/></tr><tr><td>Location</td><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x0003c;0.001</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.149</td></tr><tr><td align="left">&#x02003;&#x02003;Lower</td><td align="center">672</td><td align="center">72.1</td><td align="center">42.1</td><td align="center"/><td align="center">75</td><td align="center">83.3</td><td align="center">85.3</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Middle</td><td align="center">99</td><td align="center">10.6</td><td align="center">37.6</td><td align="center"/><td align="center">9</td><td align="center">10.0</td><td align="center">66.7</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Upper</td><td align="center">115</td><td align="center">12.3</td><td align="center">36.5</td><td align="center"/><td align="center">6</td><td align="center">6.7</td><td align="center">66.7</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Entire</td><td align="center">46</td><td align="center">4.9</td><td align="center">25.4</td><td align="center"/><td align="center">0</td><td align="center">0.0</td><td align="center">0.0</td><td align="center"/></tr><tr><td>Macroscopic Type</td><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x0003c;0.001</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Early stage</td><td align="center">90</td><td align="center">10.7</td><td align="center">81.0</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Borrmann I</td><td align="center">30</td><td align="center">2.1</td><td align="center">42.1</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Borrmann II</td><td align="center">145</td><td align="center">15.6</td><td align="center">40.7</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Borrmann III</td><td align="center">614</td><td align="center">65.9</td><td align="center">34.2</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Borrmann IV</td><td align="center">52</td><td align="center">5.6</td><td align="center">13.7</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Lauren grade</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.003</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.218</td></tr><tr><td align="left">&#x02003;&#x02003;Intestinal</td><td align="center">455</td><td align="center">48.8</td><td align="center">50.4</td><td align="center"/><td align="center">38</td><td align="center">42.2</td><td align="center">86.5</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Diffuse</td><td align="center">477</td><td align="center">51.2</td><td align="center">37.1</td><td align="center"/><td align="center">52</td><td align="center">57.8</td><td align="center">73.1</td><td align="center"/></tr><tr><td>Histologic type</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.334</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.263</td></tr><tr><td align="left">&#x02003;&#x02003;Mixed-type</td><td align="center">272</td><td align="center">29.2</td><td align="center">40.3</td><td align="center"/><td align="center">37</td><td align="center">41.1</td><td align="center">61.3</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Well-differentiated</td><td align="center">61</td><td align="center">6.5</td><td align="center">57.9</td><td align="center"/><td align="center">7</td><td align="center">7.8</td><td align="center">83.7</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Medium-differentiated</td><td align="center">112</td><td align="center">12.0</td><td align="center">43.7</td><td align="center"/><td align="center">8</td><td align="center">8.9</td><td align="center">53.9</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Poorly-differentiated</td><td align="center">365</td><td align="center">39.2</td><td align="center">37.5</td><td align="center"/><td align="center">34</td><td align="center">37.8</td><td align="center">40.2</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Mucinous</td><td align="center">58</td><td align="center">6.2</td><td align="center">38.6</td><td align="center"/><td align="center">1</td><td align="center">1.1</td><td align="center">100.0</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Signet-ring cell</td><td align="center">29</td><td align="center">3.1</td><td align="center">47.8</td><td align="center"/><td align="center">3</td><td align="center">3.3</td><td align="center">33.3</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Undifferentiated</td><td align="center">30</td><td align="center">3.2</td><td align="center">21.4</td><td align="center"/><td align="center">0</td><td align="center">0.0</td><td align="center">0.0</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Squamous cell</td><td align="center">5</td><td align="center">0.5</td><td align="center">25.0</td><td align="center"/><td align="center">0</td><td align="center">0.0</td><td align="center">0.0</td><td align="center"/></tr><tr><td>Histologic type 2</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.504</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.958</td></tr><tr><td align="left">&#x02003;&#x02003;Differentiated</td><td align="center">380</td><td align="center">40.8</td><td align="center">37.6</td><td align="center"/><td align="center">59</td><td align="center">65.6</td><td align="center">83.1</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Undifferentiated</td><td align="center">552</td><td align="center">59.2</td><td align="center">40.5</td><td align="center"/><td align="center">31</td><td align="center">34.4</td><td align="center">80.6</td><td align="center"/></tr><tr><td>Histologic type 3</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.032</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.016</td></tr><tr><td align="left">&#x02003;&#x02003;Singal-type</td><td align="center">684</td><td align="center">73.3</td><td align="center">39.3</td><td align="center"/><td align="center">56</td><td align="center">62.2</td><td align="center">89.1</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Mixed-type</td><td align="center">246</td><td align="center">26.4</td><td align="center">39.3</td><td align="center"/><td align="center">34</td><td align="center">37.8</td><td align="center">72.4</td><td align="center"/></tr><tr><td>Histologic Grading</td><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x0003c;0.001</td><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;&#x02003;1</td><td align="center">63</td><td align="center">6.8</td><td align="center">82.5</td><td align="center"/><td align="center">30</td><td align="center">30.0</td><td align="center">93.3</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;2</td><td align="center">352</td><td align="center">37.7</td><td align="center">62.0</td><td align="center"/><td align="center">45</td><td align="center">50.0</td><td align="center">88.6</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;3</td><td align="center">399</td><td align="center">42.8</td><td align="center">26.2</td><td align="center"/><td align="center">17</td><td align="center">18.9</td><td align="center">78.6</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;4</td><td align="center">118</td><td align="center">12.6</td><td align="center">6.8</td><td align="center"/><td align="center">1</td><td align="center">1.1</td><td align="center">0.0</td><td align="center"/></tr><tr><td>T Stage</td><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x0003c;0.001</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;T1</td><td align="center">90</td><td align="center">9.7</td><td align="center">82.2</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;T2</td><td align="center">185</td><td align="center">19.8</td><td align="center">50.8</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;T3</td><td align="center">418</td><td align="center">44.8</td><td align="center">36.5</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;T4</td><td align="center">239</td><td align="center">25.6</td><td align="center">19.0</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>N Stage</td><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x0003c;0.001</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.06</td></tr><tr><td align="left">&#x02003;&#x02003;N0</td><td align="center">288</td><td align="center">30.9</td><td align="center">63.8</td><td align="center"/><td align="center">65</td><td align="center">72.2</td><td align="center">86.2</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;N1</td><td align="center">168</td><td align="center">18.0</td><td align="center">43.7</td><td align="center"/><td align="center">13</td><td align="center">14.4</td><td align="center">76.9</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;N2</td><td align="center">189</td><td align="center">20.3</td><td align="center">34.0</td><td align="center"/><td align="center">10</td><td align="center">11.1</td><td align="center">70.0</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;N3</td><td align="center">287</td><td align="center">22.5</td><td align="center">12.2</td><td align="center"/><td align="center">2</td><td align="center">2.2</td><td align="center">50.0</td><td align="center"/></tr><tr><td>Lymphovascular invasion</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.032</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Negative</td><td align="center">208</td><td align="center">22.3</td><td align="center">40.7</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Positive</td><td align="center">724</td><td align="center">77.7</td><td align="center">22.6</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Peritoneal metastasis</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.022</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Absent</td><td align="center">889</td><td align="center">88.9</td><td align="center">39.8</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Present</td><td align="center">43</td><td align="center">11.1</td><td align="center">19.5</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Hepatic metastasis</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.014</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Absent</td><td align="center">878</td><td align="center">90.3</td><td align="center">38.7</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Present</td><td align="center">54</td><td align="center">9.6</td><td align="center">16.8</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr></tbody></table></table-wrap></p><p>Difference of survival reflected by tumor-related factors such as tumor size,
tumor depth, lymph node metastasis was shown in Table&#x000a0; <xref rid="Tab3" ref-type="table">3</xref>. Compared to the pure histological type, mixed histological type
gastric cancer was significant associated with tumor size, lymph node metastasis and
depth of invasion (all P&#x02009;&#x0003c;&#x02009;0.05). All the gastric cancer patients were stratified
by advanced and early stage. The 5-year survival rates of advanced and early gastric
cancer patients with mixed form were 40.8% and 83.5% respectively, which were lower
than those with pure form (50.0% and 95.8%, P&#x02009;&#x0003c;&#x02009;0.01) ( Figure&#x000a0; <xref rid="Fig2" ref-type="fig">2</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Relationship between the prognostic factors and
histological types for patients with gastric cancer</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th>Cases 932</th><th>Pure type 684 (73.61)</th><th>Mixed type 246 (26.39)</th><th>&#x003c7;2</th><th>P value</th></tr></thead><tbody><tr><td>Gender</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.532</td><td align="center">0.466</td></tr><tr><td align="left">&#x02003;&#x02003;Male</td><td align="center">669</td><td align="center">488</td><td align="center">181</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Female</td><td align="center">263</td><td align="center">198</td><td align="center">65</td><td align="center"/><td align="center"/></tr><tr><td>Age(years)</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.039</td><td align="center">0.843</td></tr><tr><td align="left">&#x02003;&#x02003;&#x02264;65</td><td align="center">533</td><td align="center">391</td><td align="center">142</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;&#x0003e;65</td><td align="center">399</td><td align="center">295</td><td align="center">104</td><td align="center"/><td align="center"/></tr><tr><td>Size</td><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x0003c;0.001</td><td align="center">0.983</td></tr><tr><td align="left">&#x02003;&#x02003;&#x02264;4&#x000a0;cm</td><td align="center">224</td><td align="center">165</td><td align="center">59</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;&#x0003e;4&#x000a0;cm</td><td align="center">708</td><td align="center">521</td><td align="center">187</td><td align="center"/><td align="center"/></tr><tr><td>Location</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.081</td><td align="center">0.96</td></tr><tr><td align="left">&#x02003;&#x02003;Lower</td><td align="center">672</td><td align="center">495</td><td align="center">178</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Middle</td><td align="center">99</td><td align="center">103</td><td align="center">38</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Upper</td><td align="center">115</td><td align="center">88</td><td align="center">30</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Entire</td><td align="center">46</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Macroscopic Type</td><td align="center"/><td align="center"/><td align="center"/><td align="center">11.173</td><td align="center">0.018</td></tr><tr><td align="left">&#x02003;&#x02003;Early stage</td><td align="center">90</td><td align="center">66</td><td align="center">34</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Borrmann I</td><td align="center">30</td><td align="center">13</td><td align="center">7</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Borrmann II</td><td align="center">145</td><td align="center">119</td><td align="center">26</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Borrmann III</td><td align="center">614</td><td align="center">453</td><td align="center">161</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Borrmann IV</td><td align="center">52</td><td align="center">35</td><td align="center">17</td><td align="center"/><td align="center"/></tr><tr><td>Lauren grade</td><td align="center"/><td align="center"/><td align="center"/><td align="center">0.189</td><td align="center">0.003</td></tr><tr><td align="left">&#x02003;&#x02003;Intestinal</td><td align="center">455</td><td align="center">368</td><td align="center">128</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Diffuse</td><td align="center">477</td><td align="center">318</td><td align="center">118</td><td align="center"/><td align="center"/></tr><tr><td>T Stage</td><td align="center"/><td align="center"/><td align="center"/><td align="center">9.629</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;&#x02003;T1</td><td align="center">90</td><td align="center">56</td><td align="center">34</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;T2</td><td align="center">185</td><td align="center">140</td><td align="center">45</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;T3</td><td align="center">418</td><td align="center">321</td><td align="center">97</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;T4</td><td align="center">239</td><td align="center">169</td><td align="center">70</td><td align="center"/><td align="center"/></tr><tr><td>N Stage</td><td align="center"/><td align="center"/><td align="center"/><td align="center">3.043</td><td align="center">0.551</td></tr><tr><td align="left">&#x02003;&#x02003;N0</td><td align="center">288</td><td align="center">213</td><td align="center">75</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;N1</td><td align="center">168</td><td align="center">131</td><td align="center">37</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;N2</td><td align="center">189</td><td align="center">135</td><td align="center">54</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;N3</td><td align="center">287</td><td align="center">207</td><td align="center">80</td><td align="center"/><td align="center"/></tr><tr><td>Lymphovascular invasion</td><td align="center"/><td align="center"/><td align="center"/><td align="center">8.794</td><td align="center">0.038</td></tr><tr><td align="left">&#x02003;&#x02003;Negative</td><td align="center">208</td><td align="center">378</td><td align="center">121</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Positive</td><td align="center">724</td><td align="center">300</td><td align="center">124</td><td align="center"/><td align="center"/></tr><tr><td>Peritoneal metastasis</td><td align="center"/><td align="center"/><td align="center"/><td align="center">10.322</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;&#x02003;Absent</td><td align="center">889</td><td align="center">672</td><td align="center">215</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Present</td><td align="center">43</td><td align="center">12</td><td align="center">31</td><td align="center"/><td align="center"/></tr><tr><td>Hepatic metastasis</td><td align="center"/><td align="center"/><td align="center"/><td align="center">11.523</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;&#x02003;Absent</td><td align="center">878</td><td align="center">667</td><td align="center">209</td><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Present</td><td align="center">54</td><td align="center">17</td><td align="center">37</td><td align="center"/><td align="center"/></tr></tbody></table></table-wrap><fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>The 5-year survival rates of gastric cancer patients
with mixed form were lower than those with pure form, especially for early
stage. (A)</bold> Survival rates of all gastric cancer patients with
mixed form were 48.2% and single form were 53.3%, P&#x02009;=&#x02009;0.305. <bold>(B)</bold> Survival rates of early gastric cancer patients
with mixed form were 83.5% and single form were 95.8%, P&#x02009;&#x0003c;&#x02009;0.01.
<bold>(C)</bold> Survival rates of early gastric
cancer patients with mixed form were 40.8% and single form were 50.0%,
P&#x02009;=&#x02009;0.037.</p></caption><graphic xlink:href="12885_2014_5019_Fig2_HTML" id="d30e2521"/></fig></p><p>Patients stratified by Histological grading of 214 (55.9%), 182 (28.4%), 492
(15.7%) and 44 (28.4%) defined Histological stage I, II, III and IV, respectively.
Statistically significant difference with stratification of early and advanced stage
could be observed between patients with the histological grading score,
respectively. Mixed histological type gastric cancer had worse prognosis in early
and advanced stage (Table&#x000a0; <xref rid="Tab2" ref-type="table">2</xref>). No
significant difference was observed regarding gender and age of the patients.
Significant correlation was observed between H grading scores and all of the
tumor-related factors (Table&#x000a0; <xref rid="Tab4" ref-type="table">4</xref>).The T, N,
and TNM stage are the best classification system to classify overall survival of
patients with gastric carcinoma, however, there is no effective methodology to
evaluate the prognosis of early stage. The 5-year survival rates of gastric cancer
patients stratified by histological grading showed there is no superiority compared
to T stage and N stage, but the 5-year survival rates of patients with early stage
stratified by histological grading was much better than N stage in predicting the
prognosis of the early stages, P&#x02009;&#x0003c;&#x02009;0.01. Significant difference could be observed
in survival curves between the early and advanced stage for the same patients,
respectively (Figure&#x000a0; <xref rid="Fig3" ref-type="fig">3</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>
<bold>Comparison of relationship between Histological
grading and prognositic factors</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="4">Histological grading</th><th>P</th></tr><tr><th align="left">Variables</th><th>H1 (&#x02264;2)</th><th>H2 (2&#x02013;3)</th><th>H3 (3&#x02013;4)</th><th>H4 (4&#x02013;5)</th><th/></tr></thead><tbody><tr><td>Size</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;&#x02003;&#x02264;4&#x000a0;cm</td><td align="center">61</td><td align="center">39</td><td align="center">117</td><td align="center">7</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;&#x0003e;4&#x000a0;cm</td><td align="center">153</td><td align="center">143</td><td align="center">375</td><td align="center">37</td><td align="center"/></tr><tr><td>Location</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Lower</td><td align="center">150</td><td align="center">130</td><td align="center">358</td><td align="center">35</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Middle</td><td align="center">34</td><td align="center">25</td><td align="center">76</td><td align="center">6</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Upper</td><td align="center">30</td><td align="center">27</td><td align="center">58</td><td align="center">3</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Entire</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Macroscopic Type</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;&#x02003;Early stage</td><td align="center">31</td><td align="center">18</td><td align="center">49</td><td align="center">2</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Borrmann I</td><td align="center">10</td><td align="center">2</td><td align="center">7</td><td align="center">1</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Borrmann II</td><td align="center">43</td><td align="center">33</td><td align="center">63</td><td align="center">6</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Borrmann III</td><td align="center">127</td><td align="center">123</td><td align="center">334</td><td align="center">30</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Borrmann IV</td><td align="center">3</td><td align="center">6</td><td align="center">38</td><td align="center">5</td><td align="center"/></tr><tr><td>Lauren grade</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;&#x02003;Intestinal</td><td align="center">169</td><td align="center">127</td><td align="center">194</td><td align="center">6</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Diffuse</td><td align="center">45</td><td align="center">55</td><td align="center">298</td><td align="center">38</td><td align="center"/></tr><tr><td>Histologic type</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;&#x02003;Differentiated</td><td align="center">164</td><td align="center">141</td><td align="center">72</td><td align="center">3</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Un-differentiated</td><td align="center">50</td><td align="center">41</td><td align="center">420</td><td align="center">41</td><td align="center"/></tr><tr><td>Depth of tumor</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;&#x02003;T1</td><td align="center">30</td><td align="center">17</td><td align="center">42</td><td align="center">1</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;T2</td><td align="center">46</td><td align="center">36</td><td align="center">95</td><td align="center">8</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;T3</td><td align="center">92</td><td align="center">89</td><td align="center">223</td><td align="center">14</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;T4</td><td align="center">46</td><td align="center">40</td><td align="center">132</td><td align="center">21</td><td align="center"/></tr><tr><td>Node metastasis</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;&#x02003;N0</td><td align="center">87</td><td align="center">55</td><td align="center">137</td><td align="center">9</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;N1</td><td align="center">42</td><td align="center">37</td><td align="center">83</td><td align="center">6</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;N2</td><td align="center">44</td><td align="center">40</td><td align="center">96</td><td align="center">9</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;N3</td><td align="center">41</td><td align="center">50</td><td align="center">176</td><td align="center">20</td><td align="center"/></tr><tr><td>Lymphovascular invasion</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;&#x02003;Negative</td><td align="center">145</td><td align="center">104</td><td align="center">240</td><td align="center">10</td><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Positive</td><td align="center">77</td><td align="center">76</td><td align="center">249</td><td align="center">35</td><td align="center"/></tr><tr><td>Peritoneal metastasis</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Absent</td><td align="center">889</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Present</td><td align="center">43</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td>Hepatic metastasis</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Absent</td><td align="center">878</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="left">&#x02003;&#x02003;Present</td><td align="center">54</td><td align="center"/><td align="center"/><td align="center"/><td align="center"/></tr></tbody></table></table-wrap><fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>The 5-year survival rates of gastric cancer patients
stratified by histological grading. (A)</bold> showed there is no
superiority compared to N stage <bold>(B)</bold> and T
stage <bold>(C)</bold>, but the 5-year survival rates of
patients with early stage stratified by histological grading <bold>(D)</bold> was much better than N stage <bold>(E)</bold> in predicting the prognosis of the early
stages, P&#x02009;&#x0003c;&#x02009;0.01. Significant difference could be observed in survival
curves between the early and advanced stage for the same patients,
respectively.</p></caption><graphic xlink:href="12885_2014_5019_Fig3_HTML" id="d30e3168"/></fig></p><p>The multivariate Cox stepwise proportional hazard model identified Macroscopic
type (HR, 1.226, P &#x0003c;0.001), Histological grading (HR, 1.316, P &#x0003c;0.001), T
stage (HR, 1.340, P &#x0003c;0.001), N stage (HR, 1.425, P &#x0003c;0.001) as independent
predictors of prognosis. In the early gastric cancer, Histological grading (HR,
1.533, P &#x0003c;0.001), Tumor size (HR, 1.412, P &#x0003c;0.001) and N stage (HR, 1.213, P
&#x0003c;0.001) as independent predictors of prognosis, histological grading were proved
to be the highest HR (Table&#x000a0; <xref rid="Tab5" ref-type="table">5</xref>).<table-wrap id="Tab5"><label>Table 5</label><caption><p>
<bold>Mutivariate analysis of the prognostic factors for
patients with gastric cancer in overall and early stage</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th colspan="3">Overall</th><th colspan="3">Early stage</th></tr><tr><th/><th>HR</th><th>95% CI</th><th>P value</th><th>HR</th><th>95% CI</th><th>P value</th></tr></thead><tbody><tr><td align="center">Size</td><td align="center">1.220</td><td align="center">0.958-1.554</td><td align="center">0.107</td><td align="center">1.412</td><td align="center">1.026-1.545</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="center">Macroscopic type</td><td align="center">1.226</td><td align="center">1.086-1.385</td><td align="center">&#x0003c;0.001</td><td align="center">1.365</td><td align="center">0.922-1.463</td><td align="center">0.103</td></tr><tr><td align="center">Lauren grade</td><td align="center">1.181</td><td align="center">0.894-1.076</td><td align="center">0.684</td><td align="center">1.133</td><td align="center">0.754-1.042</td><td align="center">0.725</td></tr><tr><td align="center">Histologic type</td><td align="center">1.136</td><td align="center">0.764-1.352</td><td align="center">0.722</td><td align="center">1.136</td><td align="center">0.764-1.352</td><td align="center">0.722</td></tr><tr><td align="center">Histologic grading</td><td align="center">1.316</td><td align="center">1.182-1.465</td><td align="center">&#x0003c;0.001</td><td align="center">1.533</td><td align="center">0.838-1.734</td><td align="center">&#x0003c;0.001</td></tr><tr><td align="center">N Stage</td><td align="center">1.425</td><td align="center">1.328-1.529</td><td align="center">&#x0003c;0.001</td><td align="center">1.213</td><td align="center">1.096-1.416</td><td align="center">0.036</td></tr><tr><td align="center">T Stage</td><td align="center">1.340</td><td align="center">1.181-1.522</td><td align="center">&#x0003c;0.001</td><td align="center"/><td align="center"/><td align="center"/></tr><tr><td align="center">Distant metastasis</td><td align="center">1.215</td><td align="center">0.935-1.650</td><td align="center">0.116</td><td align="center"/><td align="center"/><td align="center"/></tr></tbody></table></table-wrap></p><sec id="Sec6"><title>Discussion</title><p>Generally, tumor stage composed of depth of tumor, lymph node metastasis, and
distant metastasis, might account for the most powerful indicator for the
prognosis in the majority of malignant tumors [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Conventional
histopathological variables that have been correlated with prognosis of many
malignant neoplasms plays an important role in prognostic score, such as Gleason
score of prostate cancer, Child-pugh classification of hepatocellular carcinoma,
SBR, WHO score of breast cancer [<xref ref-type="bibr" rid="CR8">8</xref>,
<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Nevertheless, for gastric cancer, separated from other cancers, the prognostic
value of these factors has not been consistently recognized. It has been reported
that there is no relationship between gastric histological type and prognosis,
there is no comprehensive pathological conditions or anything about gastric
histopathological differentiation in the reflection of gastric cancer staging and
prognosis [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>However, the practical value of some of histopathological variables is limited
due to complexity of gastric histological composition, coexistence of different
malignancy subtypes and ambiguity of tumor biological behaviors [<xref ref-type="bibr" rid="CR19">19</xref>]. Despite their histological variability,
usually one of four patterns predominates. The diagnosis is based on the
predominant histological pattern [<xref ref-type="bibr" rid="CR20">20</xref>]. Histologically, most subtypes of carcinoma occur in early
gastric cancer in either pure or mixed forms. We performed this study to compare
pure or mixed gastric cancer forms of prognosis, The 5-year survival rates of
advanced and early gastric cancer patients with mixed form were 40.8% and 83.5%
respectively, which were lower than those with pure form (50.0% and 95.8%,
P&#x02009;&#x0003c;&#x02009;0.01).</p><p>Proportion of mixed forms gastric cancer patients with N0 stage were
significantly lower than with a pure type, patients of mixed type are more likely
to lymph node metastasis. Mixed forms were significantly correlated with T stage,
so patients were stratified into early and advanced stage, univariate analysis and
survival curve showed 5 -year survival of mixed type of early gastric cancer was
significantly lower than that that of a pure type, and there was little difference
in the advanced stage.</p><p>With the histological grading score, there is significantly different between
the 5-year survival curves of H Stage, prognosis of early gastric cancer could be
identified obviously, which is not reflected in any other current classification.
Indeed, statistically significant difference with so strict stratification was
observed between patients with H Stage 1&#x02013;4.</p><p>The T, N, or TNM classification system could exert an excellent ability to
classify overall survival of patients with gastric carcinoma also in the current
study. However, in early gastric cancers, only small mucosal (&#x0003c;4&#x000a0;cm),
superficial (&#x0003e;4&#x000a0;cm) and PenA, PenB may have a low incidence of lymph node
metastasis with good prognosis after surgery [<xref ref-type="bibr" rid="CR21">21</xref>]. There is no effective methodology to evaluate the prognosis
of early gastric cancer. Our new histological grading provides a new tragedy to
identify the prognosis of early gastric cancer.</p><p>Of course, TNM classification system could exert an excellent ability to
classify survival of patients with gastric carcinoma also in the current study.
Therefore, H grading system newly devised as well as TNM classification system
could classify the prognosis of patients with gastric carcinoma with a strict
stratification. This score system would provide objective information regarding
the outcome of patients treated with curative resection for gastric
carcinoma.</p><p>In conclusion, H Stage that can be utilized in the majority of the institutes
would be quite simple criteria to predict prognosis of gastric carcinoma with a
strict stratification.</p></sec></sec><sec id="Sec7" sec-type="conclusions"><title>Conclusions</title><p>The histological score that we developed in the research exert an excellent
ability to classify survival of patients with gastric carcinoma, it could classify
the prognosis of patients with gastric carcinoma with a strict stratification. The
histological score is an independent factor of gastric cancer. It also provides a
new strategy and parameter for evaluating the biological behavior and prognosis of
gastric cancer.</p></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>HX conceived and designed the study; ZZ, ZS and JW collected and analyzed
the data; ZZ and XS wrote the manuscript; ZW and XZ provided critical revisions that
are important for the intellectual content; HX approved the final version of the
manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by grants from the National Natural Science
Foundation of China (81302129) and General Project of Liaoning Provincial Education
Department (L2013291). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>S</given-names></name><name><surname>Crumley</surname><given-names>AB</given-names></name><name><surname>Fullarton</surname><given-names>GM</given-names></name><name><surname>Horgan</surname><given-names>PG</given-names></name><name><surname>McMillan</surname><given-names>DC</given-names></name></person-group><article-title>Comparison of the prognostic value of tumour and
patient related factors in patients undergoing potentially curative resection of
gastric cancer</article-title><source>Am J Surg</source><year>2012</year><volume>204</volume><fpage>294</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/j.amjsurg.2011.10.015</pub-id><?supplied-pmid 22444831?><pub-id pub-id-type="pmid">22444831</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohri</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Ohi</surname><given-names>M</given-names></name><name><surname>Yokoe</surname><given-names>T</given-names></name><name><surname>Miki</surname><given-names>C</given-names></name><name><surname>Kusunoki</surname><given-names>M</given-names></name></person-group><article-title>Prognostic significance of host- and tumor-related
factors in patients with gastric cancer</article-title><source>World J Surg</source><year>2010</year><volume>34</volume><fpage>285</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1007/s00268-009-0302-1</pub-id><?supplied-pmid 19997918?><pub-id pub-id-type="pmid">19997918</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saragoni</surname><given-names>L</given-names></name><name><surname>Morgagni</surname><given-names>P</given-names></name><name><surname>Gardini</surname><given-names>A</given-names></name><name><surname>Marfisi</surname><given-names>C</given-names></name><name><surname>Vittimberga</surname><given-names>G</given-names></name><name><surname>Garcea</surname><given-names>D</given-names></name><name><surname>Scarpi</surname><given-names>E</given-names></name></person-group><article-title>Early gastric cancer: diagnosis, staging, and clinical
impact. Evaluation of 530 patients. New elements for an updated definition and
classification</article-title><source>Gastric Cancer</source><year>2013</year><volume>16</volume><fpage>549</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1007/s10120-013-0233-2</pub-id><?supplied-pmid 23423491?><pub-id pub-id-type="pmid">23423491</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>K</given-names></name><name><surname>Langer</surname><given-names>R</given-names></name><name><surname>Reim</surname><given-names>D</given-names></name><name><surname>Novotny</surname><given-names>A</given-names></name><name><surname>Meyer zum Buschenfelde</surname><given-names>C</given-names></name><name><surname>Engel</surname><given-names>J</given-names></name><name><surname>Friess</surname><given-names>H</given-names></name><name><surname>Hofler</surname><given-names>H</given-names></name></person-group><article-title>Significance of histopathological tumor regression
after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480
cases</article-title><source>Ann Surg</source><year>2011</year><volume>253</volume><fpage>934</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e318216f449</pub-id><?supplied-pmid 21490451?><pub-id pub-id-type="pmid">21490451</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>GY</given-names></name><name><surname>Liu</surname><given-names>KH</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>YZ</given-names></name><name><surname>Wu</surname><given-names>XH</given-names></name><name><surname>Lu</surname><given-names>YZ</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Yin</surname><given-names>P</given-names></name><name><surname>Liao</surname><given-names>HF</given-names></name><name><surname>Su</surname><given-names>JQ</given-names></name></person-group><article-title>Alterations of tumor-related genes do not exactly
match the histopathological grade in gastric adenocarcinomas</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><fpage>1129</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.3748/wjg.v16.i9.1129</pub-id><?supplied-pmid 20205286?><pub-id pub-id-type="pmid">20205286</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheney</surname><given-names>MD</given-names></name><name><surname>Chen</surname><given-names>MH</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Phillips</surname><given-names>JG</given-names></name><name><surname>Loffredo</surname><given-names>MJ</given-names></name><name><surname>D'Amico</surname><given-names>AV</given-names></name></person-group><article-title>Greatest percentage of involved core length and the
risk of death from prostate cancer in men with highest gleason score
&#x0003e;/=7</article-title><source>Clin Genitourin Cancer</source><year>2014</year><volume>12</volume><fpage>234</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/j.clgc.2014.01.006</pub-id><?supplied-pmid 24594503?><pub-id pub-id-type="pmid">24594503</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Joo</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Woo</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>WJ</given-names></name><name><surname>Kim</surname><given-names>CM</given-names></name></person-group><article-title>Worse outcome of sorafenib therapy associated with
ascites and Child-Pugh score in advanced hepatocellular carcinoma</article-title><source>J Gastroenterol Hepatol</source><year>2013</year><volume>28</volume><fpage>1756</fpage><lpage>1761</lpage><pub-id pub-id-type="doi">10.1111/jgh.12310</pub-id><?supplied-pmid 23800278?><pub-id pub-id-type="pmid">23800278</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Doussal</surname><given-names>V</given-names></name><name><surname>Tubiana-Hulin</surname><given-names>M</given-names></name><name><surname>Friedman</surname><given-names>S</given-names></name><name><surname>Hacene</surname><given-names>K</given-names></name><name><surname>Spyratos</surname><given-names>F</given-names></name><name><surname>Brunet</surname><given-names>M</given-names></name></person-group><article-title>Prognostic value of histologic grade nuclear
components of Scarff-Bloom-Richardson (SBR). An improved score modification
based on a multivariate analysis of 1262 invasive ductal breast
carcinomas</article-title><source>Cancer</source><year>1989</year><volume>64</volume><fpage>1914</fpage><lpage>1921</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19891101)64:9&#x0003c;1914::AID-CNCR2820640926&#x0003e;3.0.CO;2-G</pub-id><?supplied-pmid 2551477?><pub-id pub-id-type="pmid">2551477</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Rhee</surname><given-names>K</given-names></name><name><surname>Huh</surname><given-names>CW</given-names></name><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Yoon</surname><given-names>SO</given-names></name><name><surname>Youn</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>SI</given-names></name></person-group><article-title>Undifferentiated early gastric cancer diagnosed as
differentiated histology based on forceps biopsy</article-title><source>Pathol Res Pract</source><year>2013</year><volume>209</volume><fpage>314</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1016/j.prp.2013.02.014</pub-id><?supplied-pmid 23598070?><pub-id pub-id-type="pmid">23598070</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takizawa</surname><given-names>K</given-names></name><name><surname>Ono</surname><given-names>H</given-names></name><name><surname>Kakushima</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Hasuike</surname><given-names>N</given-names></name><name><surname>Matsubayashi</surname><given-names>H</given-names></name><name><surname>Yamagichi</surname><given-names>Y</given-names></name><name><surname>Bando</surname><given-names>E</given-names></name><name><surname>Terashima</surname><given-names>M</given-names></name><name><surname>Kusafuka</surname><given-names>K</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name></person-group><article-title>Risk of lymph node metastases from intramucosal
gastric cancer in relation to histological types: how to manage the mixed
histological type for endoscopic submucosal dissection</article-title><source>Gastric Cancer</source><year>2013</year><volume>16</volume><fpage>531</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1007/s10120-012-0220-z</pub-id><?supplied-pmid 23192620?><pub-id pub-id-type="pmid">23192620</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Xu</surname><given-names>JB</given-names></name><name><surname>Ye</surname><given-names>JN</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>CQ</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Cai</surname><given-names>SR</given-names></name><name><surname>Zhan</surname><given-names>WH</given-names></name><name><surname>He</surname><given-names>YL</given-names></name></person-group><article-title>Pathological diagnosis is maybe non-essential for
special gastric cancer: case reports and review</article-title><source>World J Gastroenterol</source><year>2013</year><volume>19</volume><fpage>3904</fpage><lpage>3910</lpage><pub-id pub-id-type="doi">10.3748/wjg.v19.i24.3904</pub-id><?supplied-pmid 23840133?><pub-id pub-id-type="pmid">23840133</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>ER</given-names></name></person-group><article-title>Prognostic and therapeutic significance of
pathological features of breast cancer</article-title><source>NCI Monogr</source><year>1986</year><volume>1</volume><fpage>29</fpage><lpage>34</lpage><?supplied-pmid 3774014?><pub-id pub-id-type="pmid">3774014</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toki</surname><given-names>F</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Aihara</surname><given-names>R</given-names></name><name><surname>Ogata</surname><given-names>K</given-names></name><name><surname>Ando</surname><given-names>H</given-names></name><name><surname>Ohno</surname><given-names>T</given-names></name><name><surname>Mochiki</surname><given-names>E</given-names></name><name><surname>Kuwano</surname><given-names>H</given-names></name></person-group><article-title>Relationship between clinicopathological features and
mucin phenotypes of advanced gastric adenocarcinoma</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><fpage>2764</fpage><lpage>2770</lpage><pub-id pub-id-type="doi">10.3748/wjg.v16.i22.2764</pub-id><?supplied-pmid 20533596?><pub-id pub-id-type="pmid">20533596</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokota</surname><given-names>T</given-names></name><name><surname>Ishiyama</surname><given-names>S</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Teshima</surname><given-names>S</given-names></name><name><surname>Narushima</surname><given-names>Y</given-names></name><name><surname>Murata</surname><given-names>K</given-names></name><name><surname>Iwamoto</surname><given-names>K</given-names></name><name><surname>Yashima</surname><given-names>R</given-names></name><name><surname>Yamauchi</surname><given-names>H</given-names></name><name><surname>Kikuchi</surname><given-names>S</given-names></name></person-group><article-title>Lymph node metastasis as a significant prognostic
factor in gastric cancer: a multiple logistic regression analysis</article-title><source>Scand J Gastroenterol</source><year>2004</year><volume>39</volume><fpage>380</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1080/00365520310008629</pub-id><?supplied-pmid 15125471?><pub-id pub-id-type="pmid">15125471</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokota</surname><given-names>T</given-names></name><name><surname>Kunii</surname><given-names>Y</given-names></name><name><surname>Teshima</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Kikuchi</surname><given-names>S</given-names></name><name><surname>Yamauchi</surname><given-names>H</given-names></name></person-group><article-title>Significant prognostic factors in patients with early
gastric cancer</article-title><source>Int Surg</source><year>2000</year><volume>85</volume><fpage>286</fpage><lpage>290</lpage><?supplied-pmid 11589593?><pub-id pub-id-type="pmid">11589593</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babaian</surname><given-names>RJ</given-names></name><name><surname>Grunow</surname><given-names>WA</given-names></name></person-group><article-title>Reliability of Gleason grading system in comparing
prostate biopsies with total prostatectomy specimens</article-title><source>Urology</source><year>1985</year><volume>25</volume><fpage>564</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1016/0090-4295(85)90280-8</pub-id><?supplied-pmid 4012946?><pub-id pub-id-type="pmid">4012946</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albers</surname><given-names>I</given-names></name><name><surname>Hartmann</surname><given-names>H</given-names></name><name><surname>Bircher</surname><given-names>J</given-names></name><name><surname>Creutzfeldt</surname><given-names>W</given-names></name></person-group><article-title>Superiority of the Child-Pugh classification to
quantitative liver function tests for assessing prognosis of liver
cirrhosis</article-title><source>Scand J Gastroenterol</source><year>1989</year><volume>24</volume><fpage>269</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.3109/00365528909093045</pub-id><?supplied-pmid 2734585?><pub-id pub-id-type="pmid">2734585</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davessar</surname><given-names>K</given-names></name><name><surname>Pezzullo</surname><given-names>JC</given-names></name><name><surname>Kessimian</surname><given-names>N</given-names></name><name><surname>Hale</surname><given-names>JH</given-names></name><name><surname>Jauregui</surname><given-names>HO</given-names></name></person-group><article-title>Gastric adenocarcinoma: prognostic significance of
several pathologic parameters and histologic classifications</article-title><source>Hum Pathol</source><year>1990</year><volume>21</volume><fpage>325</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1016/0046-8177(90)90234-V</pub-id><?supplied-pmid 2312109?><pub-id pub-id-type="pmid">2312109</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundmann</surname><given-names>E</given-names></name><name><surname>Schlake</surname><given-names>W</given-names></name></person-group><article-title>Histological classification of gastric cancer from
initial to advanced stages</article-title><source>Pathol Res Pract</source><year>1982</year><volume>173</volume><fpage>260</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/S0344-0338(82)80088-5</pub-id><?supplied-pmid 6289288?><pub-id pub-id-type="pmid">6289288</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoshita</surname><given-names>N</given-names></name><name><surname>Yanagisawa</surname><given-names>A</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Kitagawa</surname><given-names>T</given-names></name><name><surname>Hirokawa</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>Y</given-names></name></person-group><article-title>Pathological characteristics of gastric carcinomas in
the very old</article-title><source>Jpn J Cancer Res</source><year>1998</year><volume>89</volume><fpage>1087</fpage><lpage>1092</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.1998.tb00501.x</pub-id><?supplied-pmid 9849590?><pub-id pub-id-type="pmid">9849590</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flejou</surname><given-names>JF</given-names></name></person-group><article-title>[WHO Classification of digestive tumors: the fourth
edition]</article-title><source>Ann Pathol</source><year>2011</year><volume>31</volume><fpage>S27</fpage><lpage>S31</lpage><pub-id pub-id-type="doi">10.1016/j.annpat.2011.08.001</pub-id><?supplied-pmid 22054452?><pub-id pub-id-type="pmid">22054452</pub-id></element-citation></ref><ref-list id="BSec1"><title>Pre-publication history</title><ref id="CR22"><mixed-citation publication-type="other">The pre-publication history for this paper can be accessed here: <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/14/663/prepub">http://www.biomedcentral.com/1471-2407/14/663/prepub</ext-link></mixed-citation></ref></ref-list></ref-list></back></article>
